ID27576A - USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES - Google Patents

USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES

Info

Publication number
ID27576A
ID27576A IDW20002433A ID20002433A ID27576A ID 27576 A ID27576 A ID 27576A ID W20002433 A IDW20002433 A ID W20002433A ID 20002433 A ID20002433 A ID 20002433A ID 27576 A ID27576 A ID 27576A
Authority
ID
Indonesia
Prior art keywords
cycosporine
autoimun
treatment
disease diseases
diseases
Prior art date
Application number
IDW20002433A
Other languages
Indonesian (id)
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID27576A publication Critical patent/ID27576A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IDW20002433A 1998-06-02 1999-05-31 USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES ID27576A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds

Publications (1)

Publication Number Publication Date
ID27576A true ID27576A (en) 2001-04-12

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002433A ID27576A (en) 1998-06-02 1999-05-31 USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES

Country Status (17)

Country Link
EP (1) EP1082130A1 (en)
JP (2) JP4523154B2 (en)
KR (1) KR20010043969A (en)
CN (1) CN1304315A (en)
AU (1) AU750422B2 (en)
BR (1) BR9910860A (en)
CA (1) CA2333315A1 (en)
GB (1) GB9811854D0 (en)
HU (1) HUP0102142A3 (en)
ID (1) ID27576A (en)
IL (1) IL139589A0 (en)
NO (1) NO20006113L (en)
PL (1) PL344451A1 (en)
SK (1) SK18142000A3 (en)
TW (2) TWI250021B (en)
WO (1) WO1999062540A1 (en)
ZA (1) ZA200006464B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1123001A (en) 1999-10-27 2001-05-08 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
CA2423313A1 (en) * 2000-09-29 2002-04-04 Z. Robert Zhong Methods of treating inflammatory and immune reactions and compositions therefor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20080194470A1 (en) * 2004-04-08 2008-08-14 Novartis Ag Nim811 In Cerebral Ischemia and Brain and Spinal Cord Injury
MX2007000503A (en) 2004-07-14 2007-03-08 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv).
AU2005290984B2 (en) * 2004-10-01 2010-09-09 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
EP1830871A1 (en) 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment
MX2007007721A (en) * 2004-12-23 2007-08-14 Novartis Ag Compounds for flaviviridae treatment.
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
JP2007112775A (en) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine Use of cyclosporines in treatment of cytomegalovirus infection
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
EP2509615A1 (en) * 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
US20140212381A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (en) * 1995-07-04 1999-09-08 Sandoz Ag A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations

Also Published As

Publication number Publication date
TWI250022B (en) 2006-03-01
HUP0102142A3 (en) 2001-12-28
WO1999062540A1 (en) 1999-12-09
HUP0102142A2 (en) 2001-11-28
AU4372499A (en) 1999-12-20
NO20006113L (en) 2001-01-25
IL139589A0 (en) 2002-02-10
GB9811854D0 (en) 1998-07-29
JP2002516873A (en) 2002-06-11
BR9910860A (en) 2001-03-06
JP2010059177A (en) 2010-03-18
TW200522975A (en) 2005-07-16
JP4523154B2 (en) 2010-08-11
PL344451A1 (en) 2001-11-05
ZA200006464B (en) 2002-03-11
CA2333315A1 (en) 1999-12-09
NO20006113D0 (en) 2000-12-01
AU750422B2 (en) 2002-07-18
SK18142000A3 (en) 2001-06-11
EP1082130A1 (en) 2001-03-14
KR20010043969A (en) 2001-05-25
CN1304315A (en) 2001-07-18
TWI250021B (en) 2006-03-01

Similar Documents

Publication Publication Date Title
CY2018020I1 (en) TREATMENT OF ROMRE'S DISEASE
FIU20060389U0 (en) Treatment of bone diseases
PT1083889E (en) TETRA-HYDROFOLANTALINE COMPOUNDS AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
ATE472325T1 (en) INTRACORPORAL MEDICATIONS FOR THE PHOTODYNAMIC TREATMENT OF DISEASES
NO994014L (en) Arylsulfonamides and analogs thereof and their use in the treatment of neurodegenerative diseases
PT1028954E (en) IMIDAZOLES SUBSTITUIDOS UTEIS IN THE TREATMENT OF INFLAMMATORY DISEASES
DK1031346T3 (en) Non-invasive skin vaccination
EE9900469A (en) Sulfonamides for the treatment of endothelin-mediated diseases
EE200100480A (en) Xenon for use in the treatment of nerve poisoning
ATE271038T1 (en) 4-PHENYLPIPERIDINE FOR THE TREATMENT OF PRUTITIC SKIN DISEASES
EE200300214A (en) Sulfonamides for the treatment of endothelin-mediated diseases
ID27576A (en) USE OF CYCOSPORINE IN TREATMENT OF AUTOIMUN DISEASE DISEASES
ID28111A (en) METHODS TO IMPROVE SKIN HEALTH
DE69524138D1 (en) Skin treatment agents
IS6966A (en) Cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
NO20005179D0 (en) Drug treatment
IS6967A (en) New cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
ATE258035T1 (en) DISPOSABLE HUMAN FEATURES
ID23528A (en) THERAPEUTIC TREATMENT FOR SKIN DISORDERS
ITMI20001216A0 (en) USE OF ALOE-EMODIN IN THE TREATMENT OF NEOPLASTIC DISEASES OF NEUROECTODERMIC ORIGIN
ID30458A (en) OSANETAN IN TREATMENT OF SOUL DISORDERS
PT1200447E (en) OXAZINOCARBAZOLES FOR THE TREATMENT OF DISEASES OF THE SNC
NO20010044L (en) Use of texaphyrins in macrophage-mediated diseases
EP1322778A4 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
EP1107778A4 (en) Treatment of disease states